So not everyone’s happy about the new NCEP cholesterol guidelines. Drug companies funding studies is absolutely nothing new. In this case, the data is sound and peer-reviewed. True, it’s not a completely ideal source of funds, but the money’s got to come from somewhere.
Related posts:
- The mirage of HDL cholesterol
- Brewer: Falling HDLs due to generic statins?
- Zero tolerance for adverse drug events
- Who monitors clinical guidelines?
- Is Cheerios really a drug, and why is the FDA targeting the cereal?
- Torcetrapib failed even worse than thought
- Drug reps getting cranky
KevinMD.com on Facebook
Comments on this entry are closed.